Omzo vs Enhance MD: Semaglutide and Tirzepatide Pricing and Programs
Comparing Omzo vs Enhance MD quickly: Omzo centers on personalized, clinician-guided compounded semaglutide starting at $179, while Enhance MD advertises semaglutide from $49 the first month with flat-rate pricing. Early verdict: choose Omzo if you want clinician-reviewed personalized plans and FSA/HSA eligibility; choose Enhance MD if lowest first-month cost and flat-rate dosing matter most.
Explore Omzo clinician-guided plans
Key differences at a glance: Omzo vs Enhance MD
This side-by-side comparison focuses on the most distinctive differences supported by the sources: starting pricing, pricing model and dose escalation, compounded medication status and branded prescription handling, clinician review and program design, and tirzepatide availability and starting cost.
1. Starting price and introductory cost
Omzo lists semaglutide starting at $179 and tirzepatide starting at $279 as part of its personalized compounded offerings. Enhance MD advertises semaglutide from $49 for the first month and tirzepatide from $99 for the first month. Those Enhance MD rates are presented as first-month introductory prices.
See Enhance MD first-month pricing
2. Pricing model and dose escalation
Enhance MD emphasizes flat-rate pricing where the ongoing rate stays the same at every dose with no fee escalation during titration. Enhance MD notes the $49/$99 rates are first-month prices and that ongoing flat-rate pricing applies thereafter. Omzo shows starting fees but does not present a flat-rate, no escalation claim in the captured evidence; Omzo describes personalized plans and fees tied to clinician-guided programs.
3. Compounded medications and branded prescriptions
Both providers offer compounded semaglutide and tirzepatide options and include the regulatory note that compounded medications are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality. Omzo additionally says its providers may write prescriptions for branded FDA-approved medications such as Ozempic or Wegovy, but Omzo does not sell, dispense, or ship branded medications and patients are responsible for filling those prescriptions at their chosen pharmacy.
4. Clinician oversight and program framing
Omzo positions its service as clinician-guided plans reviewed by licensed U.S. providers and clarifies that clinical services are provided by third party networks of U.S.-licensed clinicians who determine eligibility and make final prescribing decisions. Enhance MD describes a clinician-directed review process and cites real-world volume, noting it has treated more than 10,000 patients. Both emphasize clinician review and that treatment is available only when a licensed clinician determines it is medically appropriate.
5. Tirzepatide availability and cost signals
Omzo lists tirzepatide starting at $279. Enhance MD offers tirzepatide from $99 for the first month and notes tirzepatide is available on its platform with flat-rate ongoing pricing after the introductory period.
| Criteria | Omzo | Enhance MD |
|---|---|---|
| Semaglutide starting price | Starting at $179 | From $49 first month |
| Tirzepatide starting price | Starting at $279 | From $99 first month |
| Pricing model | Clinician-guided pricing; fees included in program | Flat-rate pricing; same price at every dose after introductory period |
| Medication type and regulation | Compounded medications offered; not FDA-approved; may prescribe branded meds for pharmacy fill | Compounded medications offered; not FDA-approved; direct-pay model |
| Clinician oversight and volume | Licensed U.S. providers via third party networks; clinician-guided plans | Clinician-directed review; 10,000+ patients treated |
| FSA / HSA eligibility | FSA & HSA eligible (stated) | Not specified in captured evidence |
Review Omzo medication options and starting fees
Clinical claims, regulation, and limitations
Both sources clearly state that compounded medications are not FDA-approved and have not been reviewed by the FDA for safety, effectiveness, or quality. Omzo explicitly notes that its compounded drugs are prepared by a state-licensed sterile compounding pharmacy and that branded prescriptions, if written, must be filled separately by the patient. Enhance MD states its compounds are clinician-directed and that treatment is provided only when a licensed clinician determines it is medically appropriate.
Start with Enhance MD clinician-directed intake
Bottom line and how to choose
Omzo vs Enhance MD splits primarily on cost structure and program framing. Enhance MD is the lower-cost entry option with semaglutide from $49 first month and flat-rate ongoing pricing, plus a multi-compound offering and stated high patient volume. Omzo emphasizes personalized, clinician-guided plans, FSA/HSA eligibility, and the option for providers to prescribe branded medications that patients must fill at their pharmacy.
Choose Omzo if you prioritize clinician-guided personalization, FSA or HSA eligibility, and options that include provider-issued prescriptions for branded products that you would fill independently.
Choose Enhance MD if your priority is the lowest first-month cost and predictable flat-rate pricing across doses, or if you want both semaglutide and tirzepatide options with a low introductory price.
Primary keyword: Omzo vs Enhance MD